Profile cover photo
Profile photo
Matinas BioPharma
13 followers -
Matinas is a clinical-stage biopharmaceutical company focused on developing innovative anti-infectives for orphan indications.
Matinas is a clinical-stage biopharmaceutical company focused on developing innovative anti-infectives for orphan indications.

13 followers
About
Matinas BioPharma's posts

Post has attachment

Post has attachment

Post has attachment
Matinas today announced the presentation of positive preclinical efficacy data at The American Society for Microbiology’s ASM Microbe 2017 Conference, demonstrating its lead anti-infective product candidate MAT2203, which utilizes the Company’s proprietary cochleate lipid-crystal nano-particle drug delivery technology, exhibits positive results as an effective oral anti-fungal agent for the treatment of cryptococcal meningoencephalitis. Read today's press release for additional details on the poster presentation:

Post has attachment
Matinas announced today that Jerome D. Jabbour, Co-Founder and President, will present at the 2017 Jefferies Global Healthcare Conference on Friday, June 9, 2017 at 10:00 a.m. ET in New York, NY. Mr. Jabbour will provide an update of the Company’s Phase 2 clinical program of its lead antifungal product candidate, MAT2203, and discuss the clinical program for product candidate, MAT2501. A live video webcast of the presentation will be available on the Company website. Find additional information here:

Post has attachment
Matinas announced today that two abstracts will be presented in poster sessions at The American Society for Microbiology’s (ASM Microbe/ICAAC 2017) scientific meeting being held June 1–5. Raphael Mannino, Ph.D., Chief Scientific Officer of Matinas, will present an abstract on MAT2203 on June 2nd from 12:45 p.m. – 2:45 p.m. CDT. Alexandra Freeman, M.D., of the National Institute of Allergy and Infectious Diseases (NIAID) Laboratory of Clinical Infectious Diseases, will provide a summary of interim results from the ongoing open-label, NIH-sponsored Phase 2a clinical study of MAT2203 in immunocompromised patients on June 3rd from 12:15 p.m. – 2:15 p.m. CDT. Additional details here:

Post has attachment
Serious opportunistic fungal infections are most often diagnosed or suspected in individuals with compromised immune systems. Matinas is developing an encochleated formulation of Amphotericin B, MAT2203, as potential treatment for these patients.

Post has attachment
Opportunistic infections are caused by fungi, parasites, viruses and bacteria that take advantage of individuals with weakened immune systems, such as those with HIV.

Post has attachment

Post has attachment

Post has attachment
Earlier this year, World Health Organization (WHO) reported the 12 types of bacteria that pose the greatest threats and were deemed priorities in urgent need of new antibiotics. Find out more:
Wait while more posts are being loaded